Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer

European Urology
Antoine ItalianoKarim Fizazi

Abstract

There are no data on the patterns of care and outcome of very elderly patients with castration-resistant prostate cancer (CRPC) treated with docetaxel. To assess the routine use of first-line docetaxel-based chemotherapy in CRPC patients aged >75 yr. We reviewed the clinical files of 175 patients aged > or =75 yr with CRPC treated with first-line docetaxel in nine French tertiary care cancer centres from 2000 to 2007. Response rate, survival, and adverse events (AE). Median age was 78 yr. Ninety-five patients (54%) received a standard 3-wk regimen (SR), and 80 patients (46%) received an adapted regimen (AR) delivered on a weekly schedule with various times for rest periods. Patients treated with an AR were older (>80 yr) and had poorer performance status (PS; > or =2) than patients treated with the SR. The prostate-specific antigen (PSA) response rates were not significantly different between the standard and adapted treatment groups (71% vs 68%, p=0.79). The median progression-free survival (PFS) was 7.4 mo. The median overall survival (OS) was 15 mo. The incidence of grade 3 or 4 AEs was 46% and was correlated with poor PS and the presence of visceral disease but not with the regimen. Early discontinuation of treatment becaus...Continue Reading

References

Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Oren SmaletzMichael W Kattan
Mar 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susan HalabiNicholas J Vogelzang
May 18, 2004·Cancer Treatment Reviews·Hans Wildiers, Robert Paridaens
Jul 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hironobu MinamiHiroyasu Ogata
Aug 21, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J TaberneroJ Baselga
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
Dec 16, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R GervaisE Quoix
Feb 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Albert J ten TijeSharyn D Baker
Aug 12, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G FreyerE Pujade-Lauraine
Dec 24, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C CampsUNKNOWN Spanish Lung Cancer Group
Oct 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Arti HurriaClifford Hudis
May 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martine Extermann, Arti Hurria
Jul 7, 2007·Critical Reviews in Oncology/hematology·Ulrich WeddingStefan Schmitz
Sep 15, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Huub A A M MaasA N Machteld Wymenga
Nov 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andrew J ArmstrongMario Eisenberger
Jan 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dominik R BertholdIan F Tannock
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun

❮ Previous
Next ❯

Citations

May 23, 2013·Der Urologe. Ausg. A·G HatibogluS Pahernik
Mar 30, 2012·Journal of the National Cancer Institute·William DaleUNKNOWN Cancer and Aging Research Group
May 14, 2014·Nature Reviews. Clinical Oncology·Gautam G JhaBadrinath R Konety
Feb 23, 2013·Acta Oncologica·Ingela Franck LissbrantPär Stattin
Nov 19, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J N GraffC N Sternberg
Feb 14, 2012·Clinics in Geriatric Medicine·Deepak Kilari, Supriya Gupta Mohile
Dec 26, 2015·Der Urologe. Ausg. A·J Hess
Oct 20, 2009·Critical Reviews in Oncology/hematology·Jean-Pierre DrozCora N Sternberg
Jun 3, 2009·Cancer Treatment Reviews·Cristina FalciJean Pierre Droz
Oct 18, 2015·Clinics in Geriatric Medicine·Breton RousselWilliam Dale
Jul 25, 2009·BJU International·Karim Fizazi, Kurt Miller
Jul 15, 2015·Prostate International·Hui-Li WongMark Rosenthal
Aug 21, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Brian S SealPamela D Allen
Apr 8, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·John M FitzpatrickRonald de Wit
Oct 11, 2014·Journal of Geriatric Oncology·Raya Leibowitz-AmitAnthony M Joshua
Jan 25, 2017·Nature Reviews. Urology·Antonello VecciaOrazio Caffo
Jul 30, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chunkit FungSupriya Gupta Mohile
Jul 7, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dominique VodovarFrédéric Pène
Feb 2, 2018·Scandinavian Journal of Urology·Ingela Franck LissbrantPär Stattin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.